P-glycoprotein recognition of substrates and circumvention through rational drug design

被引:184
|
作者
Raub, Thomas J. [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
active efflux; circumvention; drug resistance; drug membrane transport; P-glycoprotein; structure-activity relationship;
D O I
10.1021/mp0500871
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It is now well recognized that membrane efflux transporters, especially P-glycoprotein (P-gp; ABCB1), play a role in determining the absorption, distribution, metabolism, excretion, and toxicology behaviors of some drugs and molecules in development. An investment in screening structure-activity relationship (SAR) is warranted in early discovery when exposure and/or target activity in an in vivo efficacy model is not achieved and P-gp efflux is identified as a rate-limiting factor. However, the amount of investment in SAR must be placed into perspective by assessing the risks associated with the intended therapeutic target, the potency and margin of safety of the compound, the intended patient population(s), and the market competition. The task of rationally designing a chemistry strategy for circumventing a limiting P-gp interaction can be daunting. The necessity of retaining biological potency and metabolic stability places restrictions on what can be done, and the factors for P-gp recognition of substrates are complicated and poorly understood. The parameters within the assays that affect overall pump efficiency or net efflux, such as passive diffusion, membrane partitioning, and molecular interaction between pump and substrate, should be understood when interpreting data sets associated with chemistry around a scaffold. No single, functional group alone is often the cause, but one group can accentuate the recognition points existing within a scaffold. This can be likened to a rheostat, rather than an on/off switch, where addition or removal of a key group can increase or decrease the pumping efficiency. The most practical approach to de-emphasize the limiting effects of P-gp on a particular scaffold is to increase passive diffusion. Efflux pumping efficiency may be overcome when passive diffusion is fast enough. Eliminating, or substituting with fewer, groups that solvate in water, or decreasing their hydrogen bonding capacity, and adding halogen groups can increase passive diffusion. Reducing molecular size, replacing electronegative atoms, blocking or masking H-bond donors with N-alkylation or bulky flanking groups, introducing constrained conformation, or by promoting intramolecular hydrogen bonds are all examples of steps to take. This review discusses our understanding of how P-gp recognizes and pumps compounds as substrates and describes cases where structural changes were made in a chemical scaffold to circumvent the effects of P-gp interactions.
引用
收藏
页码:3 / 25
页数:23
相关论文
共 50 条
  • [1] Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
    Loo, TW
    Clarke, DM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (02) : 419 - 422
  • [2] LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance
    Zhitomirsky, Benny
    Farber, Hodaya
    Assaraf, Yehuda G.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22 (04) : 2131 - 2141
  • [3] Characterization of β-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein
    Bachmakov, I
    Werner, U
    Endress, B
    Auge, D
    Fromm, MF
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2006, 20 (03) : 273 - 282
  • [4] Identification of Smac mimetics as novel substrates for p-glycoprotein
    Hugle, Manuela
    Czaplinski, Sebastian
    Habermann, Karoline
    Vogler, Meike
    Fulda, Simone
    CANCER LETTERS, 2019, 440 : 126 - 134
  • [5] Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding
    Seelig, Anna
    Gerebtzoff, Gregori
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (05) : 733 - 752
  • [6] P-glycoprotein Inhibition for Optimal Drug Delivery
    Amin, Md. Lutful
    DRUG TARGET INSIGHTS, 2013, 7 : 27 - 34
  • [7] The role of P-glycoprotein in rational pharmacotherapy in cardiology
    Shulkin, A. V.
    Yakusheva, E. N.
    Popova, N. M.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2013, 9 (06) : 701 - 707
  • [8] Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein
    Dilger, K
    Schwab, M
    Fromm, MF
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (05) : 578 - 583
  • [9] Testosterone and androstenedione are endogenous substrates of P-glycoprotein
    Yano, Kentaro
    Seto, Saeka
    Kamioka, Hiroki
    Mizoi, Kenta
    Ogihara, Takuo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 520 (01) : 166 - 170
  • [10] P-glycoprotein, a source of drug interactions
    Roussin, Fanny
    Picard, Nicolas
    ACTUALITES PHARMACEUTIQUES, 2020, 59 (601): : 48 - 52